RxDoctor Payments DataLook up a doctor →

Michael Carter, MD

Family Medicine · Huntsville, ALNPI 1427045152

Payments from drug & device makers

$3,378,519in general payments, 2019–2025

Across 826 payments — averaging $4090.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$1.8M
  • Pfizer$1M
  • IBSA Institut Biochimique SA$284K
  • Janssen Research & Development, LLC$207K
  • Biohaven Pharmaceuticals, Inc.$15K
  • Biohaven Pharmaceutical Holding Company Ltd.$10K
  • plus $14K from 32 others

What the payments were for

  • Speaking & faculty fees$4004%
  • Food & beverage$8,97295%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,378,519 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$277,738
Medicare patients
455
Services billed
4,802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$89,094
JardianceEmpagliflozin62$63,288
EliquisApixaban69$56,067
TrulicityDulaglutide43$47,723
RybelsusSemaglutide18$27,874
FarxigaDapagliflozin Propanediol24$24,859
Repatha SureclickEvolocumab27$24,832
JanuviaSitagliptin Phosphate25$24,407
MyrbetriqMirabegron17$16,647
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,523
XareltoRivaroxaban13$9,753
Levothyroxine Sodium265$6,198
EntrestoSacubitril/Valsartan12$6,179
SynthroidLevothyroxine Sodium52$5,337
PremarinEstrogens, Conjugated16$4,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,752$116,969117 claims
Boehringer IngelheimJardiance$346$63,28862 claims
PfizerEliquis, Premarin$1,005,575$61,04785 claims
Lilly USA, LLCTrulicity$934$47,72343 claims
AstraZenecaFarxiga$1,011$24,85924 claims
MerckJanuvia$119$24,40725 claims
Astellas Pharma US IncMyrbetriq$32$16,64717 claims
GSKTrelegy Ellipta$5,499$13,52318 claims
NovartisEntresto$12$6,17912 claims
AbbVieSynthroid$429$5,33752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →